McKesson (MCK) Projected to Post Quarterly Earnings on Thursday

Key Points

• Q4 2026 earnings due May 7, 2026 after close: Analysts expect EPS of $11.57 and revenue of $101.36B, and McKesson has set FY2026 guidance at $38.80–$39.20 EPS (consensus ~ $39).
• In the last reported quarter (Feb. 4) McKesson beat estimates with EPS of $9.34 vs. $9.19 and revenue of $106.16B (up 11.4% YoY); the stock has a market cap of about $100.9B and a P/E near 23.7.
• Recent corporate actions include selling its stake in Medical‑Surgical Solutions, securing a new $5.0 billion revolving credit facility, declaring a $0.82 quarterly dividend ($3.28 annual, ~0.4% yield), and insider selling of roughly 3,592 shares (~$3.52M) over the last three months.

McKesson (NYSE:MCK - Get Free Report) will likely be issuing its Q4 2026 results after the market closes on Thursday, May 7th. Analysts expect the company to announce earnings of $11.57 per share and revenue of $101.3596 billion for the quarter. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. Investors may visit the the company's upcoming Q4 2026 earning results page for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:30 PM ET.

McKesson (NYSE:MCK - Get Free Report) last issued its earnings results on Wednesday, February 4th. The company reported $9.34 earnings per share for the quarter, topping analysts' consensus estimates of $9.19 by $0.15. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The business had revenue of $106.16 billion during the quarter, compared to analyst estimates of $105.98 billion. During the same quarter in the previous year, the firm earned $8.03 EPS. McKesson's revenue was up 11.4% on a year-over-year basis. On average, analysts expect McKesson to post $39 EPS for the current fiscal year and $44 EPS for the next fiscal year.

McKesson Stock Performance

Shares of NYSE:MCK opened at $823.68 on Thursday. McKesson has a fifty-two week low of $637.00 and a fifty-two week high of $999.00. The business has a 50-day simple moving average of $897.30 and a two-hundred day simple moving average of $859.47. The firm has a market cap of $100.89 billion, a price-to-earnings ratio of 23.69, a price-to-earnings-growth ratio of 1.20 and a beta of 0.42.

McKesson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, July 1st. Shareholders of record on Monday, June 1st will be paid a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Monday, June 1st. McKesson's payout ratio is currently 9.43%.

Key Headlines Impacting McKesson

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson sold its stake in Medical‑Surgical Solutions, a move that could unlock cash and simplify the company’s portfolio — potentially supporting buybacks or redeployment of capital. McKesson sells stake in Medical-Surgical Solutions
• Positive Sentiment: McKesson Canada secured national distribution for naturemary, expanding reach into thousands of pharmacies — a small but constructive revenue/market-access win in consumer and retail channels. naturemary Secures National Distribution with McKesson Canada, Unlocking Access to Thousands of Pharmacies
• Positive Sentiment: McKesson put a new $5.0 billion senior unsecured revolving credit facility in place, strengthening liquidity and debt flexibility ahead of potential strategic investments or cash-return programs. McKesson Secures New $5 Billion Revolving Credit Facility
• Neutral Sentiment: Analysts are re‑weighing McKesson’s valuation relative to its biosimilars/co‑manufacturing optionality; fair value estimates moved only marginally, but individual price targets diverge — highlights evolving thesis but no consensus catalyst yet. How The Narrative On McKesson (MCK) Is Shifting Around Biosimilars And Valuation Premium
• Neutral Sentiment: Investor pieces pitching McKesson as a way to play GLP‑1 channel growth highlight upside scenarios but are speculative and unlikely to move fundamentals immediately. GLP-1 trade? McKesson is your stock, this investor says
• Neutral Sentiment: Reports that lawmakers have been increasing holdings in McKesson attracted press attention — notable for optics but not a direct operational driver. Lawmakers increase stakes in McKesson, Boeing, Alphabet amid scrutiny
• Negative Sentiment: Market coverage noted McKesson fell more steeply than the broader market today, reflecting investor selling pressure and concerns over the stock’s premium to historical averages. McKesson (MCK) Falls More Steeply Than Broader Market: What Investors Need to Know
• Negative Sentiment: Competitor coverage (William Blair initiating Cardinal Health at Outperform) highlights investor appetite for distributor exposure elsewhere, which could pressure McKesson’s multiple if flows shift to peers. William Blair Initiates Cardinal Health at Outperform: Is the Pharma Distributor a Stealth Compounder?

Insider Buying and Selling

In related news, EVP Michele Lau sold 2,725 shares of the firm's stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $990.00, for a total transaction of $2,697,750.00. Following the sale, the executive vice president owned 3,247 shares of the company's stock, valued at $3,214,530. This trade represents a 45.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Leann B. Smith sold 190 shares of the firm's stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $945.00, for a total value of $179,550.00. Following the sale, the executive vice president directly owned 2,989 shares in the company, valued at approximately $2,824,605. The trade was a 5.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 3,592 shares of company stock worth $3,518,555 in the last three months. 0.08% of the stock is owned by company insiders.

Institutional Investors Weigh In On McKesson

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MCK. IHT Wealth Management LLC grew its stake in shares of McKesson by 0.9% during the 4th quarter. IHT Wealth Management LLC now owns 1,196 shares of the company's stock worth $981,000 after purchasing an additional 11 shares during the period. River Wealth Advisors LLC grew its stake in shares of McKesson by 0.9% during the 4th quarter. River Wealth Advisors LLC now owns 1,383 shares of the company's stock worth $1,134,000 after purchasing an additional 13 shares during the period. DF Dent & Co. Inc. grew its stake in shares of McKesson by 1.1% during the 4th quarter. DF Dent & Co. Inc. now owns 1,238 shares of the company's stock worth $1,016,000 after purchasing an additional 14 shares during the period. Bey Douglas LLC grew its stake in shares of McKesson by 0.3% during the 4th quarter. Bey Douglas LLC now owns 5,833 shares of the company's stock worth $4,785,000 after purchasing an additional 15 shares during the period. Finally, Cynosure Group LLC grew its stake in shares of McKesson by 2.9% during the 4th quarter. Cynosure Group LLC now owns 568 shares of the company's stock worth $466,000 after purchasing an additional 16 shares during the period. 85.07% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

MCK has been the subject of a number of recent research reports. Morgan Stanley restated an "overweight" rating and set a $966.00 price target on shares of McKesson in a research note on Thursday, January 29th. Robert W. Baird set a $968.00 price objective on McKesson in a research note on Wednesday, January 14th. Wells Fargo & Company boosted their price target on McKesson from $914.00 to $925.00 and gave the stock an "equal weight" rating in a report on Thursday, February 5th. Bank of America decreased their price target on McKesson from $1,040.00 to $1,000.00 and set a "buy" rating on the stock in a report on Monday, April 6th. Finally, UBS Group decreased their price target on McKesson from $1,012.00 to $1,000.00 and set a "buy" rating on the stock in a report on Wednesday, April 22nd. Fourteen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $972.27.

McKesson Company Profile

McKesson Corporation NYSE: MCK is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company's core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.